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Abstract— Hippocampal and entorhinal cortex as scanned 
in Magnetic Resonance Imaging (MRI), are two of the most 
commonly used Regions of Interest (ROIs) for the assessment of 
Alzheimer’s disease (AD). Both structures are used for the 
classification between Normal Controls (NC), Mild Cognitive 
Impairment (MCI) and AD subjects and for the disease 
prognosis.  The objective of this study was to evaluate how the 
volume of these two structures changes between the following 
groups: NC vs AD, NC vs MCI, MCI vs MCI converters (MCIc 
- subjects who had converted to AD within 48 months), and AD 
vs MCIc subjects. Both structures were significantly reduced in 
volume for MCIc and AD subjects compared to NC. For both 
MCI and MCIc groups, the atrophy rate was correlated for both 
structures. In AD subjects, entorhinal cortex was more affected 
by atrophy. In conclusion, structural MRI and volumetric 
measurements of the hippocampus and entorhinal cortex can be 
used as early signs for the assessment of AD, and this is in 
agreement with previous studies. 
 
Keywords-Alzheimer’s disease; classification; entorhinal 
cortex; hippocampus; mild cognitive impairment; prediction 
I. INTRODUCTION 
Alzheimer’s Disease (AD) represents the most common 
form of dementia, and one of the major causes of disability in 
later life. Every 67 seconds someone in the United States 
develops Alzheimer’s and it is the 6th leading cause of death 
in the United States [1]. According to World Health 
Organization (WHO) the number of people living with 
dementia worldwide is currently estimated at 47 million and 
is projected to increase to 75 million by 2030. It is estimated 
that by 2050 the number of cases will almost triple.   
Even nowadays, the diagnosis of AD is probable and only 
post-mortem material can confirm the disease. The biopsy 
reveals deposits of amyloid-  (A ) plaque deposition and tau 
protein (Neurofibrillary Tangles - NFTs) in the brain tissue 
[2]. Thus, due to brain inaccessibility, the diagnosis is based 
on clinical and neuropsychological tests, which evaluate 
memory and language abilities. Mini Mental State 
examination (MMSE) [3] and Clinical Dementia Rating 
(CDR) [4] are commonly used in the assessment of AD.  
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However, structural changes within the brain occur years 
before the first clinical symptoms appear [5]. As a 
consequence, when a patient is diagnosed with AD by using 
only clinical and psychometric assessment the brain tissue 
will probably undergone widespread and irreversible synaptic 
loss. Furthermore, the Mild Cognitive Impairment (MCI) 
stage, which represents the transitional stage between normal 
ageing and AD, is not easily identified by cognitive tests, 
because these subjects do not have major memory problems. 
Therefore, the research community has driven a search for 
diagnostic imaging markers especially of those derived from 
quantitative Magnetic Resonance Imaging (MRI). According 
to the new diagnostic criteria [6] for the assessment of  AD, a 
subject should be positive to one of the following tests: (i) 
Medial Temporal Lobe (MTL) atrophy as seen in MRI, (ii) 
Temporoparietal hypometabolism as seen in Positron 
Emission Tomography (PET), (iii) Positivity on amyloid 
imaging as seen in PET and (iv) abnormal neuronal 
 
At the very early stage of the disease there is an inevitable 
progression of atrophy which initially affects the MTL [7] 
followed by progressive neocortical damage. The entorhinal 
cortex and hippocampus are two of the most common Regions 
of Interest (ROIs) used in both in vivo and post mortem 
investigations for the detection of AD. In vivo structural MRI 
studies [8], [9], agree with post mortem studies [10], [11], and 
indicate that the degenerative process, initiates from the 
entorhinal cortex, followed by hippocampus, amygdala and 
parahippocampal gyrus. With the disease progression, 
atrophy expands in temporal, parietal and frontal neocortices 
[12], [13] and as a consequent to the rest of the brain.  
The objective of this study was to investigate how the 
hippocampus and entorhinal cortex ROIs, are affected in AD 
and MCI subjects.  
II.  MATERIALS AND METHODS 
A. Study design and participants 
For the fulfilment of this study, data were acquired from 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
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(http://adni.loni.usc.edu/). The ADNI is an ongoing 
longitudinal multicenter effort launched in 2003 by the 
National Institute on Aging, the National Institute of 
Biomedical Imaging and Bioengineering, the Food and Drug 
Administration, private pharmaceutical companies and non-
profit organizations as a public-private partnership. Subjects 
across the US and Canada, from over 50 sites have been 
recruited to test whether serial MRI, Positron Emission 
Tomography (PET), Cerebrospinal fluid (CSF), and other 
biological markers with clinical and neuropsychological 
assessment can be used for the classification of subjects or to 
predict the progression of MCI and early AD. All the subjects 
were selected from standardized data collections and 
specifically the ADNI-1 Complete 2 and 3 year 1.5 Tesla 
datasets. These subjects had a screening scan and then at 6 
months, 1 year, 18 months (MCI only), 2, and 3 year (Normal 
Controls (NC) and MCI only). According to the ADNI 
inclusion criteria, enrolled subjects were all between 55 and 
90 years of age and spoke either English or Spanish. Each 
subject was willing, able to perform all test procedures 
described in the protocol and had a study partner able to 
provide an independent evaluation of functioning. Inclusion 
criteria for NC were: MMSE scores between 24 and 30; CDR 
of zero; absence of depression, MCI and dementia. Inclusion 
criteria for MCI were: MMSE scores between 24 and 30; 
CDR of 0.5; objective memory loss, measured by education 
adjusted scores on Wechsler Memory Scale Logical Memory 
II [14], absence of significant levels of impairment in other 
cognitive domains; absence of dementia. Inclusion criteria for 
AD were: MMSE scores between 20 and 26; CDR of 0.5 or 
1.0; NINCDS/ADRDA criteria for probable AD [6], [15]. 
Detailed description of inclusion/exclusion criteria can be 
found in the ADNI protocol 
(http://adni.loni.usc.edu/methods/documents/).  
Overall, 218 NC, 349 MCI and 165 AD subjects were 
included in this study. However, 74 MCI subjects converted 
within 48 months from their baseline scan to AD thus, MCI 
converters (MCIc) group was added to the analysis. 
B. MRI Acquisition 
All the subjects had a standardized protocol on 1.5-T MRI 
units from Siemens Medical Solutions and General Electric 
Healthcare. MR protocols included high-resolution (typically 
1.2×1.25×1.25 mm3 voxels) volumetric T1-weighted, 
inversion recovery prepared, structural images obtained in 
sagittal plane. The data had undergone gradwarp-corrected for 
(i) distortion due to gradient non-linearity [16], and (ii) 
corrected for image intensity non-uniformity using N3 [17], 
and B1 non-uniformity [18] and (iii) scaling-corrected based 
on phantom measures. 
C. Measurements extraction 
T1-weighted volumetric 3D sagittal magnetization 
prepared rapid gradient-echo (MPRAGE) scans were collected 
for each subject. Volume measures of the hippocampus and 
entorhinal cortex were reconstructed using FreeSurfer v5.3 
software, Martinos Center for Biomedical Imaging, Harvard-
MIT, Boston USA [19]. Freesurfer is based on Surface-based 
Analysis (SBA) and derives morphometric measures from 
geometric models of the cortical surface. It uses a probabilistic 
atlas derived from a manually labeled training set of expert 
measurements and automatically performs subcortical and 
cortical segmentation of the brain.  
Briefly, the Freesurfer surface-based pipeline stages 
include: (i) volume registration using MNI305 atlas [20], (ii) 
voxel intensity allocation and classification as White Matter 
(WM) or other tissue, (iii) separation of both hemispheres and 
exclusion of the cerebellum and brain stem, (iv) surface 
generation (for each hemisphere) by tiling the outside of the 
WM mass for that hemisphere, (v) this surface is refined to 
follow the intensity gradients between the WM and Gray 
Matter (GM) (this is referred to as the white surface) and (vi) 
white surface is nudged to follow the intensity gradients 
between the GM and CSF (pial surface) [21]. 
The Freesurfer subcortical-based pipeline consists of 5 
stages which label subcortical tissues and calculates their 
volumes. These stages are: (i) affine registration with MNI305, 
(ii) initial volumetric labeling, (iii) intensity variation 
correction, (iv) dimensional nonlinear volumetric alignment to 
the MNI305 atlas, and (v) label atlas is built from a training 
set. For more details of Freesurfer streams, the reader is 
referred to [19], [22]. 
III. RESULTS 
Table I tabulates the volume differences between the 
hippocampus and the entorhinal cortex between the 3 groups 
(from their baseline scan) through ANOVA statistics. STATA 
V14 was used and the level of significance was =0.05.  
Table II illustrates the percentage of volume reduction of 
hippocampus and entorhinal cortex between the 3 groups 
from the baseline scans.  
 
TABLE I. VOLUMES (MEAN (SD)) OF ENTORHINAL CORTEX AND 






































Values in parentheses are SD NC=Normal cognition; MCI=mild cognitive impairment; 
AD=Alzheimer’s disease; 
* P<0.001 for MCI Vs NC, and AD Vs NC 
† P<0.001 for AD Vs MCI 
 
TABLE I . VOLUME REDUCTION (%) OF ENTORHINAL CORTEX AND 










AD Vs NC -26.08* -25.68* -22.52* -21.82* 
MCI Vs NC -14.25* -12.71* -12.69* -12.45* 
AD Vs MCI -13.80* -14.86* -11.28* -10.69* 
GLOSSARY: NC=Normal cognition; MCI=mild cognitive impairment; 
AD=Alzheimer’s disease; ERC: Entorhinal cortex; Hip.: Hippocampus. 
*p<0.05 
 
Figure 1 shows the percentage changes of the mean 
volumes for the two regions for all subjects. According to 
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table 1 the total left entorhinal cortex volume of all NC was 
1944 (SD 367) mm3 and 1936 (SD 411) mm3 for the right. 
These values were significantly reduced for the MCI subjects, 
to 1667 (SD 457) mm3 and 1689 (SD 455) mm3 for left and 
right entorhinal cortex respectively. For the same groups, the 
hippocampal volumes were reduced from 3290 (SD 435) mm3 
and 3323 (458) mm3 to 2873 (SD 501) mm3 and 2910 (SD 
526) mm3 for the left and right hippocampus respectively. 
Figure 2 represents the longitudinal volume changes 
between the two structures for the MCI and MCIc groups. 
 
 
Figure 1: Volume changes for the two structures, between the 4 groups. 
 
 
Figure 2: Volume changes between MCI and MCIc. 
IV. DISCUSSION 
From all the biomarkers used in AD, hippocampal atrophy  
as assessed on high-resolution T1-weighted MRI images is 
the best established and validated biomarker [23], [24]. 
Hippocampal measurements are more feasible due to 
hippocampus shape which allows easier segmentation and 
thus, it can be evaluated with more accuracy rather than other 
MTL structures such as entorhinal, perirhinal and 
parahippocampal cortices [25]. However, the earlier 
involvement of the entorhinal cortex was proved by many MR 
quantitative studies [26]–[28] and this was correlated with our 
results where entorhinal cortex was more affected by atrophy 
rather than the hippocampus. 
Juottonen et al. [29], used volume measurements on both 
entorhinal cortex and the hippocampus in NC and AD 
subjects and both regions had similar results on the 
classification between NC and AD subjects. Both regions 
appear to have similar pattern of atrophy. Similar to our 
results, the entorhinal cortex was more affected rather than the 
hippocampus in AD patients, however, both structures had 
similar discriminative power. 
Pennanen et al. [30] noticed that entorhinal cortex in MCI 
subjects was the region with the more severe volume loss 
providing an accuracy of 66% for the classification of NC 
from MCI subjects. On the other hand, the hippocampus 
appeared to be more affected in AD subjects which was not 
correlated with our findings were entorhinal cortex was found 
to be more affected by atrophy. More severe atrophy of the 
entorhinal cortex was also reported by Du et al. [31]. 
V. CONCLUDING REMARKS 
The major findings of this study were: 
 Both entorhinal cortex and hippocampal volumes 
were significantly reduced in MCIc group compared 
to NC subjects. 
 Compared to hippocampus, entorhinal cortex seems 
to be the region with the more severe volume loss in 
MCI converters and AD subjects. 
 The atrophy rate between entorhinal cortex and 
hippocampus was correlated for both MCI and MCIc 
groups.  
 Entorhinal cortex was more affected in the MCIc 
group and it should be preferred more for the disease 
prognosis. 
 
In conclusion, the entorhinal cortex is more affected by 
atrophy in MCI and AD subjects and it should be preferred 
for a better diagnosis of AD. Furthermore, the more severe 
involvement of the entorhinal cortex could provide a more 
accurate prediction of the disease. 
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